The dailysciencedigest’s Podcast
Prostate cancer treatment and ceramide metabolism in metastatic castration-resistant prostate cancer (mCRPC) How ceramide lipid metabolism, androgen receptor pathway inhibitors, and racial differences in cancer treatment may shape drug response Understand why ceramide profiles could help predict response to prostate cancer drugs and guide precision oncology decisions What You'll Learn: * How androgen receptor pathway inhibitors (ARPIs) like enzalutamide and abiraterone are used in metastatic castration-resistant prostate cancer—and why ~90% of patients develop resistance within 36 months * What ceramides are, how ceramide lipid metabolism works, and why molecules like C24:1 ceramide and S1P matter in cancer biology * What a high plasma C24:1 ceramide level means and how it was associated with a 35% longer median radiographic progression-free survival on ARPIs in a 2023 JCO study * How the ceramide/S1P ratio differs between Black and white men with mCRPC, including the finding of a 22% higher mean ratio in Black participants * Why racial differences in cancer treatment outcomes might be partly explained by lipid metabolism rather than just access to care or tumor burden * How ceramide metabolism could be used as a biomarker to stratify patients and personalize prostate cancer treatment strategies * Key limitations and open questions from current ceramide–mCRPC research and what needs to be validated in future clinical trials * Practical implications for clinicians, researchers, and patients interested in precision oncology and biomarker-driven prostate cancer care
100 episodios
Comentarios
0Sé la primera persona en comentar
¡Regístrate ahora y únete a la comunidad de The dailysciencedigest’s Podcast!